Shared and distinct interactions of type 1 and type 2 Epstein-Barr Nuclear Antigen 2 with the human genome.
Autoimmune disorders
ChIP-seq
EBNA2
EBV
Functional genomics
Gene regulation
Genetic risk loci
Transcription factors
Viruses
Journal
BMC genomics
ISSN: 1471-2164
Titre abrégé: BMC Genomics
Pays: England
ID NLM: 100965258
Informations de publication
Date de publication:
12 Mar 2024
12 Mar 2024
Historique:
received:
14
11
2023
accepted:
04
03
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
epublish
Résumé
There are two major genetic types of Epstein-Barr Virus (EBV): type 1 (EBV-1) and type 2 (EBV-2). EBV functions by manipulating gene expression in host B cells, using virus-encoded gene regulatory proteins including Epstein-Barr Nuclear Antigen 2 (EBNA2). While type 1 EBNA2 is known to interact with human transcription factors (hTFs) such as RBPJ, EBF1, and SPI1 (PU.1), type 2 EBNA2 shares only ~ 50% amino acid identity with type 1 and thus may have distinct binding partners, human genome binding locations, and functions. In this study, we examined genome-wide EBNA2 binding in EBV-1 and EBV-2 transformed human B cells to identify shared and unique EBNA2 interactions with the human genome, revealing thousands of type-specific EBNA2 ChIP-seq peaks. Computational predictions based on hTF motifs and subsequent ChIP-seq experiments revealed that both type 1 and 2 EBNA2 co-occupy the genome with SPI1 and AP-1 (BATF and JUNB) hTFs. However, type 1 EBNA2 showed preferential co-occupancy with EBF1, and type 2 EBNA2 preferred RBPJ. These differences in hTF co-occupancy revealed possible mechanisms underlying type-specific gene expression of known EBNA2 human target genes: MYC (shared), CXCR7 (type 1 specific), and CD21 (type 2 specific). Both type 1 and 2 EBNA2 binding events were enriched at systemic lupus erythematosus (SLE) and multiple sclerosis (MS) risk loci, while primary biliary cholangitis (PBC) risk loci were specifically enriched for type 2 peaks. This study reveals extensive type-specific EBNA2 interactions with the human genome, possible differences in EBNA2 interaction partners, and a possible new role for type 2 EBNA2 in autoimmune disorders. Our results highlight the importance of considering EBV type in the control of human gene expression and disease-related investigations.
Sections du résumé
BACKGROUND
BACKGROUND
There are two major genetic types of Epstein-Barr Virus (EBV): type 1 (EBV-1) and type 2 (EBV-2). EBV functions by manipulating gene expression in host B cells, using virus-encoded gene regulatory proteins including Epstein-Barr Nuclear Antigen 2 (EBNA2). While type 1 EBNA2 is known to interact with human transcription factors (hTFs) such as RBPJ, EBF1, and SPI1 (PU.1), type 2 EBNA2 shares only ~ 50% amino acid identity with type 1 and thus may have distinct binding partners, human genome binding locations, and functions.
RESULTS
RESULTS
In this study, we examined genome-wide EBNA2 binding in EBV-1 and EBV-2 transformed human B cells to identify shared and unique EBNA2 interactions with the human genome, revealing thousands of type-specific EBNA2 ChIP-seq peaks. Computational predictions based on hTF motifs and subsequent ChIP-seq experiments revealed that both type 1 and 2 EBNA2 co-occupy the genome with SPI1 and AP-1 (BATF and JUNB) hTFs. However, type 1 EBNA2 showed preferential co-occupancy with EBF1, and type 2 EBNA2 preferred RBPJ. These differences in hTF co-occupancy revealed possible mechanisms underlying type-specific gene expression of known EBNA2 human target genes: MYC (shared), CXCR7 (type 1 specific), and CD21 (type 2 specific). Both type 1 and 2 EBNA2 binding events were enriched at systemic lupus erythematosus (SLE) and multiple sclerosis (MS) risk loci, while primary biliary cholangitis (PBC) risk loci were specifically enriched for type 2 peaks.
CONCLUSIONS
CONCLUSIONS
This study reveals extensive type-specific EBNA2 interactions with the human genome, possible differences in EBNA2 interaction partners, and a possible new role for type 2 EBNA2 in autoimmune disorders. Our results highlight the importance of considering EBV type in the control of human gene expression and disease-related investigations.
Identifiants
pubmed: 38475709
doi: 10.1186/s12864-024-10183-8
pii: 10.1186/s12864-024-10183-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
273Subventions
Organisme : NIDCR NIH HHS
ID : K99 DE031016
Pays : United States
Organisme : NIEHS NIH HHS
ID : T32 ES007250
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI164709
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG011172
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR073228
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Faulkner GC, Krajewski AS, Crawford DH. The ins and outs of EBV infection. Trends Microbiol. 2000;8(4):185–9.
doi: 10.1016/S0966-842X(00)01742-X
Bakkalci D, Jia Y, Winter JR, Lewis JE, Taylor GS, Stagg HR. Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence. J Glob Health. 2020;10(1):010405.
pmcid: 7125417
doi: 10.7189/jogh.10.010405
Rochford R. Reframing Burkitt lymphoma: virology not epidemiology defines clinical variants. Ann Lymphoma. 2021;5:22.
pmcid: 8654190
doi: 10.21037/aol-21-18
Busson P, Keryer C, Ooka T, Corbex M. EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol. 2004;12(8):356–60.
doi: 10.1016/j.tim.2004.06.005
Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet. 2018;50(5):699–707.
pmcid: 6022759
doi: 10.1038/s41588-018-0102-3
Houen G, Trier NH. Epstein-Barr Virus and Systemic Autoimmune Diseases. Front Immunol. 2020;11:587380.
doi: 10.3389/fimmu.2020.587380
Jog NR, James JA. Epstein Barr Virus and Autoimmune Responses in Systemic Lupus Erythematosus. Front Immunol. 2020;11:623944.
doi: 10.3389/fimmu.2020.623944
Sollid LM. Epstein-Barr virus as a driver of multiple sclerosis. Sci Immunol. 2022;7(70):eabo7799.
doi: 10.1126/sciimmunol.abo7799
Hong T, Parameswaran S, Donmez OA, Miller D, Forney C, Lape M, et al. Epstein-Barr virus nuclear antigen 2 extensively rewires the human chromatin landscape at autoimmune risk loci. Genome Res. 2021;31(12):2185–98.
pmcid: 8647835
doi: 10.1101/gr.264705.120
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296–301.
doi: 10.1126/science.abj8222
Dambaugh T, Hennessy K, Chamnankit L, Kieff E. U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A. 1984;81(23):7632–6.
pmcid: 392202
doi: 10.1073/pnas.81.23.7632
Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, Kieff E. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol. 1990;64(9):4084–92.
pmcid: 247870
doi: 10.1128/jvi.64.9.4084-4092.1990
Cohen JI, Wang F, Mannick J, Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A. 1989;86(23):9558–62.
pmcid: 298536
doi: 10.1073/pnas.86.23.9558
Romero-Masters JC, Huebner SM, Ohashi M, Bristol JA, Benner BE, Barlow EA, et al. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection. PLoS Pathog. 2020;16(2):e1008365.
pmcid: 7046292
doi: 10.1371/journal.ppat.1008365
Tzellos S, Farrell PJ. Epstein-barr virus sequence variation-biology and disease. Pathogens. 2012;1(2):156–74.
pmcid: 4235690
doi: 10.3390/pathogens1020156
Crawford DH, Macsween KF, Higgins CD, Thomas R, McAulay K, Williams H, et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis. 2006;43(3):276–82.
doi: 10.1086/505400
Higgins CD, Swerdlow AJ, Macsween KF, Harrison N, Williams H, McAulay K, et al. A study of risk factors for acquisition of Epstein-Barr virus and its subtypes. J Infect Dis. 2007;195(4):474–82.
doi: 10.1086/510854
Santon A, Cristobal E, Aparicio M, Royuela A, Villar LM, Alvarez-Cermeno JC. High frequency of co-infection by Epstein-Barr virus types 1 and 2 in patients with multiple sclerosis. Mult Scler. 2011;17(11):1295–300.
doi: 10.1177/1352458511411063
Yea C, Tellier R, Chong P, Westmacott G, Marrie RA, Bar-Or A, et al. Epstein-Barr virus in oral shedding of children with multiple sclerosis. Neurology. 2013;81(16):1392–9.
pmcid: 3806908
doi: 10.1212/WNL.0b013e3182a841e4
Moon UY, Park SJ, Oh ST, Kim WU, Park SH, Lee SH, et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther. 2004;6(4):R295-302.
pmcid: 464871
doi: 10.1186/ar1181
Strobl LJ, Hofelmayr H, Stein C, Marschall G, Brielmeier M, Laux G, et al. Both Epstein-Barr viral nuclear antigen 2 (EBNA2) and activated Notch1 transactivate genes by interacting with the cellular protein RBP-J kappa. Immunobiology. 1997;198(1–3):299–306.
doi: 10.1016/S0171-2985(97)80050-2
Lu F, Chen HS, Kossenkov AV, DeWispeleare K, Won KJ, Lieberman PM. EBNA2 Drives Formation of New Chromosome Binding Sites and Target Genes for B-Cell Master Regulatory Transcription Factors RBP-jkappa and EBF1. PLoS Pathog. 2016;12(1):e1005339.
pmcid: 4709166
doi: 10.1371/journal.ppat.1005339
Maier S, Staffler G, Hartmann A, Hock J, Henning K, Grabusic K, et al. Cellular target genes of Epstein-Barr virus nuclear antigen 2. J Virol. 2006;80(19):9761–71.
pmcid: 1617228
doi: 10.1128/JVI.00665-06
Farrell PJ. Epstein-Barr Virus and Cancer. Annu Rev Pathol. 2019;14:29–53.
doi: 10.1146/annurev-pathmechdis-012418-013023
Zhao B. Epstein-Barr Virus B Cell Growth Transformation: The Nuclear Events. Viruses. 2023;15(4):832.
pmcid: 10146190
doi: 10.3390/v15040832
Kwiatkowski B, Chen SY, Schubach WH. CKII site in Epstein-Barr virus nuclear protein 2 controls binding to hSNF5/Ini1 and is important for growth transformation. J Virol. 2004;78(11):6067–72.
pmcid: 415811
doi: 10.1128/JVI.78.11.6067-6072.2004
Tzellos S, Correia PB, Karstegl CE, Cancian L, Cano-Flanagan J, McClellan MJ, et al. A single amino acid in EBNA-2 determines superior B lymphoblastoid cell line growth maintenance by Epstein-Barr virus type 1 EBNA-2. J Virol. 2014;88(16):8743–53.
pmcid: 4136291
doi: 10.1128/JVI.01000-14
Keane JT, Afrasiabi A, Schibeci SD, Swaminathan S, Parnell GP, Booth DR. The interaction of Epstein-Barr virus encoded transcription factor EBNA2 with multiple sclerosis risk loci is dependent on the risk genotype. EBioMedicine. 2021;71:103572.
pmcid: 8426200
doi: 10.1016/j.ebiom.2021.103572
Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, et al. Epstein-Barr virus genetic variants are associated with multiple sclerosis. Neurology. 2015;84(13):1362–8.
pmcid: 4388746
doi: 10.1212/WNL.0000000000001420
Ricigliano VA, Handel AE, Sandve GK, Annibali V, Ristori G, Mechelli R, et al. EBNA2 binds to genomic intervals associated with multiple sclerosis and overlaps with vitamin D receptor occupancy. PLoS ONE. 2015;10(4):e0119605.
pmcid: 4390304
doi: 10.1371/journal.pone.0119605
Waltzer L, Logeat F, Brou C, Israel A, Sergeant A, Manet E. The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements. EMBO J. 1994;13(23):5633–8.
pmcid: 395528
doi: 10.1002/j.1460-2075.1994.tb06901.x
Johannsen E, Koh E, Mosialos G, Tong X, Kieff E, Grossman SR. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU 1. J Virol. 1995;69(1):253–62.
pmcid: 188571
doi: 10.1128/jvi.69.1.253-262.1995
Laux G, Adam B, Strobl LJ, Moreau-Gachelin F. The Spi-1/PU 1 and Spi-B ets family transcription factors and the recombination signal binding protein RBP-J kappa interact with an Epstein-Barr virus nuclear antigen 2 responsive cis-element. EMBO J. 1994;13(23):5624–32.
pmcid: 395527
doi: 10.1002/j.1460-2075.1994.tb06900.x
Beer S, Wange LE, Zhang X, Kuklik-Roos C, Enard W, Hammerschmidt W, et al. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells. Proc Natl Acad Sci U S A. 2022;119(30):e2200512119.
pmcid: 9335265
doi: 10.1073/pnas.2200512119
Murata T, Noda C, Narita Y, Watanabe T, Yoshida M, Ashio K, et al. Induction of Epstein-Barr Virus Oncoprotein LMP1 by Transcription Factors AP-2 and Early B Cell Factor. J Virol. 2016;90(8):3873–89.
pmcid: 4810554
doi: 10.1128/JVI.03227-15
McClellan MJ, Wood CD, Ojeniyi O, Cooper TJ, Kanhere A, Arvey A, et al. Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming. PLoS Pathog. 2013;9(9):e1003636.
pmcid: 3771879
doi: 10.1371/journal.ppat.1003636
McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol. 2010;28(5):495–501.
pmcid: 4840234
doi: 10.1038/nbt.1630
Coleman CB, Wohlford EM, Smith NA, King CA, Ritchie JA, Baresel PC, et al. Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines. J Virol. 2015;89(4):2301–12.
doi: 10.1128/JVI.03001-14
Smith NA, Coleman CB, Gewurz BE, Rochford R. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells. J Virol. 2020;94(11):e00428-e520.
pmcid: 7269432
doi: 10.1128/JVI.00428-20
Lucchesi W, Brady G, Dittrich-Breiholz O, Kracht M, Russ R, Farrell PJ. Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2. J Virol. 2008;82(15):7456–66.
pmcid: 2493322
doi: 10.1128/JVI.00223-08
Seo J, Kocak DD, Bartelt LC, Williams CA, Barrera A, Gersbach CA, Reddy TE. AP-1 subunits converge promiscuously at enhancers to potentiate transcription. Genome Res. 2021;31(4):538–50.
pmcid: 8015846
doi: 10.1101/gr.267898.120
Vierbuchen T, Ling E, Cowley CJ, Couch CH, Wang X, Harmin DA, et al. AP-1 Transcription Factors and the BAF Complex Mediate Signal-Dependent Enhancer Selection. Mol Cell. 2017;68(6):1067-82.e12.
pmcid: 5744881
doi: 10.1016/j.molcel.2017.11.026
Lee W, Mitchell P, Tjian R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell. 1987;49(6):741–52.
doi: 10.1016/0092-8674(87)90612-X
Wolf BK, Zhao Y, McCray A, Hawk WH, Deary LT, Sugiarto NW, et al. Cooperation of chromatin remodeling SWI/SNF complex and pioneer factor AP-1 shapes 3D enhancer landscapes. Nat Struct Mol Biol. 2023;30(1):10–21.
doi: 10.1038/s41594-022-00880-x
Zhao B, Zou J, Wang H, Johannsen E, Peng CW, Quackenbush J, et al. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci U S A. 2011;108(36):14902–7.
pmcid: 3169132
doi: 10.1073/pnas.1108892108
Guo R, Zhang Y, Teng M, Jiang C, Schineller M, Zhao B, et al. DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression. Nat Microbiol. 2020;5(8):1051–63.
pmcid: 7462085
doi: 10.1038/s41564-020-0724-y
Kaiser C, Laux G, Eick D, Jochner N, Bornkamm GW, Kempkes B. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol. 1999;73(5):4481–4.
pmcid: 104340
doi: 10.1128/JVI.73.5.4481-4484.1999
Kempkes B, Spitkovsky D, Jansen-Durr P, Ellwart JW, Kremmer E, Delecluse HJ, et al. B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J. 1995;14(1):88–96.
pmcid: 398055
doi: 10.1002/j.1460-2075.1995.tb06978.x
Cancian L, Bosshard R, Lucchesi W, Karstegl CE, Farrell PJ. C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7. PLoS Pathog. 2011;7(7):e1002164.
pmcid: 3145799
doi: 10.1371/journal.ppat.1002164
Maier S, Santak M, Mantik A, Grabusic K, Kremmer E, Hammerschmidt W, Kempkes B. A somatic knockout of CBF1 in a human B-cell line reveals that induction of CD21 and CCR7 by EBNA-2 is strictly CBF1 dependent and that downregulation of immunoglobulin M is partially CBF1 independent. J Virol. 2005;79(14):8784–92.
pmcid: 1168782
doi: 10.1128/JVI.79.14.8784-8792.2005
Larcher C, Kempkes B, Kremmer E, Prodinger WM, Pawlita M, Bornkamm GW, Dierich MP. Expression of Epstein-Barr virus nuclear antigen-2 (EBNA2) induces CD21/CR2 on B and T cell lines and shedding of soluble CD21. Eur J Immunol. 1995;25(6):1713–9.
doi: 10.1002/eji.1830250634
Cordier M, Calender A, Billaud M, Zimber U, Rousselet G, Pavlish O, et al. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol. 1990;64(3):1002–13.
pmcid: 249210
doi: 10.1128/jvi.64.3.1002-1013.1990
Davis M, Malcolm S, Rabbitts TH. Chromosome translocation can occur on either side of the c-myc oncogene in Burkitt lymphoma cells. Nature. 1984;308(5956):286–8.
doi: 10.1038/308286a0
Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med. 2014;4(2):a014282.
pmcid: 3904095
doi: 10.1101/cshperspect.a014282
Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A. 1982;79(24):7837–41.
pmcid: 347444
doi: 10.1073/pnas.79.24.7837
Liang J, Zhou H, Gerdt C, Tan M, Colson T, Kaye KM, et al. Epstein-Barr virus super-enhancer eRNAs are essential for MYC oncogene expression and lymphoblast proliferation. Proc Natl Acad Sci U S A. 2016;113(49):14121–6.
pmcid: 5150416
doi: 10.1073/pnas.1616697113
Zhou H, Schmidt SC, Jiang S, Willox B, Bernhardt K, Liang J, et al. Epstein-Barr virus oncoprotein super-enhancers control B cell growth. Cell Host Microbe. 2015;17(2):205–16.
pmcid: 4539236
doi: 10.1016/j.chom.2014.12.013
Busse C, Feederle R, Schnolzer M, Behrends U, Mautner J, Delecluse HJ. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350’s functions extend beyond B-cell surface binding. J Virol. 2010;84(2):1139–47.
doi: 10.1128/JVI.01953-09
Roberts ML, Luxembourg AT, Cooper NR. Epstein-Barr virus binding to CD21, the virus receptor, activates resting B cells via an intracellular pathway that is linked to B cell infection. J Gen Virol. 1996;77(Pt 12):3077–85.
doi: 10.1099/0022-1317-77-12-3077
Tanner J, Weis J, Fearon D, Whang Y, Kieff E. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 1987;50(2):203–13.
doi: 10.1016/0092-8674(87)90216-9
Van Sciver N, Ohashi M, Nawandar DM, Pauly NP, Lee D, Makielski KR, et al. DeltaNp63alpha promotes Epstein-Barr virus latency in undifferentiated epithelial cells. PLoS Pathog. 2021;17(11):e1010045.
pmcid: 8601603
doi: 10.1371/journal.ppat.1010045
Singh DR, Nelson SE, Pawelski AS, Cantres-Velez JA, Kansra AS, Pauly NP, et al. Type 1 and Type 2 Epstein-Barr viruses induce proliferation, and inhibit differentiation, in infected telomerase-immortalized normal oral keratinocytes. PLoS Pathog. 2022;18(10):e1010868.
pmcid: 9529132
doi: 10.1371/journal.ppat.1010868
Bristol JA, Brand J, Ohashi M, Eichelberg MR, Casco A, Nelson SE, et al. Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells. PLoS Pathog. 2022;18(4):e1010453.
pmcid: 9041801
doi: 10.1371/journal.ppat.1010453
Zimber-Strobl U, Strobl LJ, Meitinger C, Hinrichs R, Sakai T, Furukawa T, et al. Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-J kappa, the homologue of Drosophila Suppressor of Hairless. EMBO J. 1994;13(20):4973–82.
pmcid: 395438
doi: 10.1002/j.1460-2075.1994.tb06824.x
Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321–7.
pmcid: 9382663
doi: 10.1038/s41586-022-04432-7
Almohmeed YH, Avenell A, Aucott L, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis. PLoS ONE. 2013;8(4):e61110.
pmcid: 3621759
doi: 10.1371/journal.pone.0061110
Hanlon P, Avenell A, Aucott L, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther. 2014;16(1):R3.
pmcid: 3978841
doi: 10.1186/ar4429
Hedstrom AK, Lima Bomfim I, Hillert J, Olsson T, Alfredsson L. Obesity interacts with infectious mononucleosis in risk of multiple sclerosis. Eur J Neurol. 2015;22(3):578-e38.
doi: 10.1111/ene.12620
James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest. 1997;100(12):3019–26.
pmcid: 508514
doi: 10.1172/JCI119856
Li ZX, Zeng S, Wu HX, Zhou Y. The risk of systemic lupus erythematosus associated with Epstein-Barr virus infection: a systematic review and meta-analysis. Clin Exp Med. 2019;19(1):23–36.
doi: 10.1007/s10238-018-0535-0
Masuoka S, Kusunoki N, Takamatsu R, Takahashi H, Tsuchiya K, Kawai S, Nanki T. Epstein-Barr virus infection and variants of Epstein-Barr nuclear antigen-1 in synovial tissues of rheumatoid arthritis. PLoS ONE. 2018;13(12):e0208957.
pmcid: 6289453
doi: 10.1371/journal.pone.0208957
McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med. 2005;11(1):85–9.
doi: 10.1038/nm1167
Middeldorp JM. Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease. Curr Top Microbiol Immunol. 2015;391:289–323.
Pender MP. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist. 2011;17(4):351–67.
pmcid: 3764840
doi: 10.1177/1073858410381531
Tsubota K, Fujishima H, Toda I, Katagiri S, Kawashima Y, Saito I. Increased levels of Epstein-Barr virus DNA in lacrimal glands of Sjogren’s syndrome patients. Acta Ophthalmol Scand. 1995;73(5):425–30.
doi: 10.1111/j.1600-0420.1995.tb00302.x
Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernan MA, Olek MJ, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA. 2001;286(24):3083–8.
doi: 10.1001/jama.286.24.3083
Bray PF, Bloomer LC, Salmon VC, Bagley MH, Larsen PD. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol. 1983;40(7):406–8.
doi: 10.1001/archneur.1983.04050070036006
Wandinger K, Jabs W, Siekhaus A, Bubel S, Trillenberg P, Wagner H, et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology. 2000;55(2):178–84.
doi: 10.1212/WNL.55.2.178
Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis Part I: the role of infection. Ann Neurol. 2007;61(4):288–99.
doi: 10.1002/ana.21117
Pakpoor J, Disanto G, Gerber JE, Dobson R, Meier UC, Giovannoni G, Ramagopalan SV. The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler. 2013;19(2):162–6.
doi: 10.1177/1352458512449682
Fraser KB, Haire M, Millar JH, McCrea S. Increased tendency to spontaneous in-vitro lymphocyte transformation in clinically active multiple sclerosis. Lancet. 1979;2(8145):175–6.
Munch M, Moller-Larsen A, Christensen T, Morling N, Hansen HJ, Haahr S. B-lymphoblastoid cell lines from multiple sclerosis patients and a healthy control producing a putative new human retrovirus and Epstein-Barr virus. Mult Scler. 1995;1(2):78–81.
doi: 10.1177/135245859500100204
Torring C, Andreasen C, Gehr N, Bjerg L, Petersen T, Hollsberg P. Higher incidence of Epstein-Barr virus-induced lymphocyte transformation in multiple sclerosis. Acta Neurol Scand. 2014;130(2):90–6.
doi: 10.1111/ane.12249
Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204(12):2899–912.
pmcid: 2118531
doi: 10.1084/jem.20071030
Pender MP, Burrows SR. Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clinical & translational immunology. 2014;3(10):e27.
doi: 10.1038/cti.2014.25
Csuka D, Simon D, Hobor R, Uray K, Prohaszka Z, Banlaki Z, et al. Serum concentration of immunoglobulin G-type antibodies against the whole Epstein-Barr nuclear antigen 1 and its aa35-58 or aa398-404 fragments in the sera of patients with systemic lupus erythematosus and multiple sclerosis. Clin Exp Immunol. 2013;171(3):255–62.
pmcid: 3569532
doi: 10.1111/cei.12022
Rand KH, Houck H, Denslow ND, Heilman KM. Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci. 2000;173(1):32–9.
doi: 10.1016/S0022-510X(99)00298-1
Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2015;172(1):3–13.
doi: 10.1016/j.neurol.2015.10.006
Ascherio A, Munger KL. Epstein-barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol. 2010;5(3):271–7.
doi: 10.1007/s11481-010-9201-3
DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol. 2006;63(6):839–44.
doi: 10.1001/archneur.63.6.noc50328
Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, Ascherio A. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA. 2005;293(20):2496–500.
doi: 10.1001/jama.293.20.2496
Ponnusamy R, Khatri R, Correia PB, Wood CD, Mancini EJ, Farrell PJ, West MJ. Increased association between Epstein-Barr virus EBNA2 from type 2 strains and the transcriptional repressor BS69 restricts EBNA2 activity. PLoS Pathog. 2019;15(7):e1007458.
pmcid: 6638984
doi: 10.1371/journal.ppat.1007458
Schmidl C, Rendeiro AF, Sheffield NC, Bock C. ChIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors. Nat Methods. 2015;12(10):963–5.
pmcid: 4589892
doi: 10.1038/nmeth.3542
Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57–74.
doi: 10.1038/nature11247
Hitz BC, Lee JW, Jolanki O, Kagda MS, Graham K, Sud P, et al. The ENCODE Uniform Analysis Pipelines. bioRxiv. 2023.
Luo Y, Hitz BC, Gabdank I, Hilton JA, Kagda MS, Lam B, et al. New developments on the Encyclopedia of DNA Elements (ENCODE) data portal. Nucleic Acids Res. 2020;48(D1):D882–9.
doi: 10.1093/nar/gkz1062
Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357–9.
pmcid: 3322381
doi: 10.1038/nmeth.1923
Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114–20.
pmcid: 4103590
doi: 10.1093/bioinformatics/btu170
Feng J, Liu T, Qin B, Zhang Y, Liu XS. Identifying ChIP-seq enrichment using MACS. Nat Protoc. 2012;7(9):1728–40.
doi: 10.1038/nprot.2012.101
Buenrostro JD, Wu B, Chang HY, Greenleaf WJ. ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. Curr Protoc Mol Biol. 2015;109:2191–9.
doi: 10.1002/0471142727.mb2129s109
Corces MR, Trevino AE, Hamilton EG, Greenside PG, Sinnott-Armstrong NA, Vesuna S, et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat Methods. 2017;14(10):959–62.
pmcid: 5623106
doi: 10.1038/nmeth.4396
Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of SAMtools and BCFtools. Gigascience. 2021;10(2):giab008.
pmcid: 7931819
doi: 10.1093/gigascience/giab008
Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature. 2012;481(7381):389–93.
pmcid: 3272464
doi: 10.1038/nature10730
Gene Ontology C, Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, et al. The Gene Ontology knowledgebase in 2023. Genetics. 2023;224(1):iyad031.
doi: 10.1093/genetics/iyad031
Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;38(4):576–89.
pmcid: 2898526
doi: 10.1016/j.molcel.2010.05.004
Lambert SA, Yang AWH, Sasse A, Cowley G, Albu M, Caddick MX, et al. Similarity regression predicts evolution of transcription factor sequence specificity. Nat Genet. 2019;51(6):981–9.
doi: 10.1038/s41588-019-0411-1
Lu X, Chen X, Forney C, Donmez O, Miller D, Parameswaran S, et al. Global discovery of lupus genetic risk variant allelic enhancer activity. Nat Commun. 2021;12(1):1611.
pmcid: 7955039
doi: 10.1038/s41467-021-21854-5
Hass MR, Brissette D, Parameswaran S, Pujato M, Donmez O, Kottyan LC, et al. Runx1 shapes the chromatin landscape via a cascade of direct and indirect targets. PLoS Genet. 2021;17(6):e1009574.
pmcid: 8219162
doi: 10.1371/journal.pgen.1009574
Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38(3):276–8.
doi: 10.1038/s41587-020-0439-x
Di Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E, Notredame C. Nextflow enables reproducible computational workflows. Nat Biotechnol. 2017;35(4):316–9.
doi: 10.1038/nbt.3820
Wang L, Nie J, Sicotte H, Li Y, Eckel-Passow JE, Dasari S, et al. Measure transcript integrity using RNA-seq data. BMC Bioinformatics. 2016;17:58.
pmcid: 4739097
doi: 10.1186/s12859-016-0922-z
Wang L, Wang S, Li W. RSeQC: quality control of RNA-seq experiments. Bioinformatics. 2012;28(16):2184–5.
doi: 10.1093/bioinformatics/bts356
Garcia-Alcalde F, Okonechnikov K, Carbonell J, Cruz LM, Gotz S, Tarazona S, et al. Qualimap: evaluating next-generation sequencing alignment data. Bioinformatics. 2012;28(20):2678–9.
doi: 10.1093/bioinformatics/bts503
Okonechnikov K, Conesa A, Garcia-Alcalde F. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics. 2016;32(2):292–4.
doi: 10.1093/bioinformatics/btv566
Sayols S, Scherzinger D, Klein H. dupRadar: a Bioconductor package for the assessment of PCR artifacts in RNA-Seq data. BMC Bioinformatics. 2016;17(1):428.
pmcid: 5073875
doi: 10.1186/s12859-016-1276-2
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.
doi: 10.1093/bioinformatics/bts635
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Schuller AP, Green R. Roadblocks and resolutions in eukaryotic translation. Nat Rev Mol Cell Biol. 2018;19(8):526–41.
pmcid: 6054806
doi: 10.1038/s41580-018-0011-4
Lassak J, Wilson DN, Jung K. Stall no more at polyproline stretches with the translation elongation factors EF-P and IF-5A. Mol Microbiol. 2016;99(2):219–35.
doi: 10.1111/mmi.13233
Joazeiro CAP. Ribosomal Stalling During Translation: Providing Substrates for Ribosome-Associated Protein Quality Control. Annu Rev Cell Dev Biol. 2017;33:343–68.
doi: 10.1146/annurev-cellbio-111315-125249